Practitioner's Docket No. MPI01-018P1RNM

REMARKS

In response to the Restriction Requirement Requirement mailed April 22, 2003 (Paper No. 6), Applicants hereby elect Group I (claims 1-7, 12, 18), drawn to polynucleotides, vectors, host cells, kit and a method of making the polypeptide, classified in class 435, subclass 69.1. Applicants have amended claims 1 and 12 and have added new claims 25 – 27 drawn to the subject matter of Group I. Support for the new claims 25-27 can be found in the claims and application as filed. No new matter has been added. Claims 1-7, 12, 18, and 25-27 are pending.

Applicants hereby reserve the right to traverse the above restriction with respect to non-elected Groups II – X claims (withdrawn claims 8-11, 13-17, and 19-24) in this or subsequent applications.

This paper is being filed timely as a request for a five month extension of time is filed concurrently herewith. No additional extensions of time are required. In the event any additional extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

Respectfully submitted,

October 20, 2003

MILLENNIUM PHARMACEUTICALS, INC.

Ву

Tracy M. Sioussat, Ph.D Registration No. 50,609

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-374-7679

Facsimile - 617-551-8820